Supplemental Material and Methods

siRNA screen
Our custom-assembled "ubiquitome" siRNA library, which consisted of 1067 siRNA pools targeting all known and assumed components of the ubiquitin and ubiquitin-like systems, was obtained in 96-well format. siRNA against REV1L and non-targeting siRNA (siCON) were used as positive and negative controls, respectively. All siRNAs were ON-TARGETplus SMARTpools® (Dharmacon). Transfections with siRNA were performed following a reverse transfection protocol (1): Briefly, 10 µl siRNA was stamped from 96-well plates of the library on to white Cellstar 96-well tissue plates (Greiner) using a dispensing robot (fluidX Xpp-721); thereafter, 10 µl of Opti-MEM® I Reduced Serum Medium (Life Technologies) containing Lipofectamine TM RNAiMAX (Life Technologies) were added to the siRNA, the plates were shaken at 900 rpm for 1 min followed by incubation for 20 min at room temperature. During this incubation cells were resuspended in DMEM and dispensed onto the wells giving 5000 cells/well and a final siRNA concentration of 10 nM. Plates were incubated for 24 hrs, after which cisplatin was added to a final concentration of 3 µM. The screen was optimized to use a cisplatin concentration to detect a moderate sensitivity equivalent to ≥80% survival in siCON-transfected cells. Furthermore, cells were exposed to cisplatin for three days to allow them progress through multiple cell cycles and the effects of cisplatin-induced damage to accumulate, thus mimicking clinically relevant chronic drug exposure.
Thereafter, cell viability was assessed by cellular ATP abundance: Briefly, cells were lysed in a combined 2x lysis buffer/luciferase assay buffer (50 mM Tris/HCl ph7. and 53BP1 (Bethyl A300-272 A-2). Alexa-Fluor 594-conjugated rabbit secondary antibodies were purchased from Invitrogen.
Kinase and caspase inhibitors
The following inhibitors and incubations were used in this study: JNK-IN8 (JNK inhibitor) used at 3 µM for 3 hours prior to addition of genotoxin (4); VX-745 (p38 inhibitor) used at 1 µM for 2 hours prior to addition of genotoxin (5); KU-55933 (ATM inhibitor) used at 10 µM for 1 hour prior to addition of genotoxin (6); ETP-46464 (ATR inhibitor) used at 5 µM for 15 minutes prior to addition of genotoxin (7) Figure S1 . HOIP depletion results in cisplatin hypersensitivity. A, schematic illustration of the siRNA secondary screen using the siRNA "ubiquitinome" library in U2OS cells. Cells were reverse-transfected with the indicated control or target siRNAs before being treated with 0-6 µM cisplatin concentrations. Cell viability was determined 72 hours following cisplatin treatment. B, cisplatin dose-dependent log 2 SF s plotted for the four individual HOIP siRNAs in comparison with siCON and siREV1L. C, HEK293 cells ere treated with the indicated siRNAs and clonogenic survival assays were carried out with 0-1 µg/ml isplatin concentrations. For each siRNA, cell viability of untreated cells was defined as 100%. Data hown in (B and C) are represented as mean ± SEM of at least two independent experiments. D and E, EK293 and U2OS cells were transfected with indicated control or target siRNAs and cell lysates were mmunobloted for HOIP, HOIL1, and SHARPIN. β-actin was used to confirm equal protein amount. (Fig. 3G ). Image J software was used to quantify immunoblots from at least 3 independent experiments; * indicates a p-value of 0.02. Data in (F) and are represented as mean ± SEM and a Student's t-test was used to calculate significance. (8) , N defined as tissue from ovarian surface epithelial cells; ii=TCGA, N defined as tissue from normal ovaries; iii= Hendrix (9) , N defined as tissue from normal ovaries; iV= Yoshihara (10) , N defined as tissue from normal peritoneum]. Data was extracted and analysed using Oncomine™ (Compendia Bioscience™, part of Life Technologies™, Ann Arbor, MI).
